GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).Read More
GeneNews (TSX:GEN), by raising additional financings via a series of transactions over the past few weeks, and filing its full year 2015 and 2016 first quarter results, has successfully resolved both the Toronto Stock Exchange continued listing review and the management cease trade order granted by the Ontario Securities Commission in March.
“The last six-to-12 months have been a challenging time for both the company and its shareholders,” executive chairman, James Howard-Tripp, said in a statement.Read More
GeneNews (TSX:GEN) has entered into a collaboration agreement with JTS Health Partners of Atlanta to accelerate adoption of GeneNews’ menu of proprietary cancer tests, including its lead ColonSentry blood-test for assessing an individual’s current risk for colorectal cancer.
JTS, a leading national healthcare management consulting and professional services firm, will also work to maximize the efficiency and effectiveness of GeneNews’ revenue cycle management operations.Read More